Photodynamic therapy of locally advanced pancreatic cancer (VERTPAC study): Final clinical results

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 8568, Issue , 2013, Pages

  Huggett, M T ^a   Jermyn, M ^b   Gillams, A ^c   Mosse, S ^a   Kent, E ^c   Bown, S G ^a   Hasan, T ^d   Pogue, B W ^b   Pereira, S P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b DARTMOUTH COLLEGE   (United States)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

pancreatic adenocarcinoma; Photodynamic therapy; verteporfin

Indexed keywords

CLINICAL SETTINGS; CT (COMPUTED TOMOGRAPHY); DOSE-ESCALATION STUDY; LOCALLY ADVANCED PANCREATIC CANCERS; NEEDLE PLACEMENT; PANCREATIC ADENOCARCINOMA; PHOTODYNAMIC THERAPY (PDT); VERTEPORFIN;

COMPUTERIZED TOMOGRAPHY; DISEASES; PATIENT MONITORING; TUMORS;

PHOTODYNAMIC THERAPY;

EID: 84878160655     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.2013648     Document Type: Conference Paper

References (23)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J. Clin., 52(1), 23-47 (2002).
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J. Clin., 49(1), 33-64 (1999).
3. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J. Am. Coll. Surg., 196(6), 954-64 (2003).
4. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol., 7(6), 593-600 (1996).
5. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15(6), 2403-13 (1997).
6. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. NEJM, 364(19), 1817-25 (2011).
7. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 27(33), 5513-8 (2009).
8. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol., 28(22), 3617-22 (2010).
9. von Wichert G, Seufferlein T, Adler G. Palliative treatment of pancreatic cancer. J. Dig. Dis., 9(1), 1-7 (2008).
10. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. The American J. Gastroenterol., 95(1), 17-31 (2000).
11. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 45(6), 931-91 (2009).
12. Barr H, Tralau CJ, Boulos PB, MacRobert AJ, Tilly R, Bown SG. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury. Photochem. Photobiol., 46(5), 795-800 (1987).
13. Bown SG, Rogowska AZ, Whitelaw DE, et al. Photodynamic therapy for cancer of the pancreas. Gut, 50(4), 549-57 (2002).
14. Wu L, Murphy RP. Photodynamic therapy: a new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration. Curr Opin Ophthalmol, 10(3), 217-20 (1999).
15. Busetti A, Soncin M, Jori G, Rodgers MA. High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. Br. J. Cancer, 79(5-6), 821-4 (1999).
16. Marcus J, Glassberg E, Dimino-Emme L, et al. Photodynamic therapy for the treatment of squamous cell carcinoma using benzoporphyrin derivative. J Dermatol Surg Oncol, 20(6), 375-82 (1994).
17. Houle JM, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina, 22(6), 691-7 (2002).
18. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. Journal Clin. Pharmacol., 42(5), 547-57 (2002).
19. Lin GC, Tsoukas ML, Lee MS, et al. Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy. Photochem. Photobiol., 68(4), 575-83 (1998).
20. Fingar VH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer, 79(11-12), 1702-8 (1999).
21. Panjehpour M, DeNovo RC, Petersen MG, et al. Photodynamic therapy using Verteporfin (benzoporphyrin derivative monoacid ring A, BPD-MA) and 630 nm laser light in canine esophagus. Lasers in surgery and medicine, 30(1), 26-30 (2002).
22. Ayaru L, Wittmann J, Macrobert AJ, Novelli M, Bown SG, Pereira SP. Photodynamic therapy using verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster. Pancreatology, 7(1), 20-7 (2007).
23. Samkoe KS, Chen A, Rizvi I, et al. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int. J. Radiation Oncology Biol. Phys., 76(1), 251-9 (2010).